This study investigated the association between LRP1B mutation and the response to immune checkpoint inhibitors (ICIs) in lung adenocarcinoma (LUAD). Using an ICI-treated LUAD cohort and the TCGA-LUAD cohort, researchers compared LRP1B-mutated and wild-type groups across various parameters. LRP1B mutation was found to be associated with increased immune cell infiltration, higher expression of immune-related genes, elevated tumor mutation burden (TMB), and neoantigens. Patients with LRP1B mutations exhibited prolonged progression-free survival (PFS). A nomogram was constructed to predict PFS based on LRP1B mutation status, TMB, and neoantigen load. The findings suggest LRP1B mutation as a potential prognostic biomarker for LUAD patients undergoing ICI treatment.
